Current and Future Medical Treatment of Androgenetic Alopecia

  • Chang-Hun Huh


The key change of androgenetic alopecia (AGA) is the thinning of hairs caused by miniaturization of hair follicles, not the shedding of hairs. As terminology implies, androgens (male sex hormones), especially dihydrotestosterone (DHT), play important roles in the pathogenesis of AGA, but no exact pathogenesis has been proven so far. However, several medications are successfully used for AGA through various mechanisms.

Many medical treatments for AGA have been introduced. Currently, oral 5AR inhibitors, including finasteride and dutasteride, and topical minoxidil are mainstream therapies. In addition, the topical 5AR inhibitor 17α-estradiol, mesotherapy, and LLLT can all be used as second-line treatments in some countries for both in men and women. Antiandrogens can be successfully used in females as well.

Cell-based treatment may be the future of medical treatment of hair loss, but more time is needed to establish effectiveness, cost, and technical details.


Androgenetic alopecia Current treatment Future treatment 


  1. 1.
    Kaufman KD, Rotonda J, Shah AK, Meehan AG. Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss). Eur J Dermatol. 2008;18:400–6.PubMedGoogle Scholar
  2. 2.
    Kaufman KD, Girman CJ, Round EM, Johnson-Levonas AO, Shah AK, Rotonda J. Progression of hair loss in men with androgenetic alopecia (male pattern hair loss): long-term (5-year) controlled observational data in placebo-treated patients. Eur J Dermatol. 2008;18:407–11.PubMedGoogle Scholar
  3. 3.
    Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC, Thiboutot DM, Lowe N, Jacobson C, Whiting D, Stieglitz S, Kraus SJ, Griffin EI, Weiss D, Carrington P, Gencheff C, Cole GW, Pariser DM, Epstein ES, Tanaka W, Dallob A, Vandormael K, Geissler L, Waldstreicher J. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999;41:550–4.PubMedGoogle Scholar
  4. 4.
    Rossi A, Cantisani C, Scarnò M, Trucchia A, Fortuna MC, Calvieri S. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatol Ther. 2011;24:455–61.CrossRefGoogle Scholar
  5. 5.
    Sato A, Takeda A. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia. J Dermatol. 2012;39:27–32.CrossRefGoogle Scholar
  6. 6.
    Yeon JH, Jung JY, Choi JW, Kim BJ, Youn SW, Park KC, Huh CH. 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol. 2011;25:211–4.CrossRefGoogle Scholar
  7. 7.
    Choi GS, Kim JH, Oh SY, Park JM, Hong JS, Lee YS, Lee WS. Safety and tolerability of the dual 5-alpha reductase inhibitor dutasteride in the treatment of androgenetic alopecia. Ann Dermatol. 2016;28:444–50.CrossRefGoogle Scholar
  8. 8.
    Jung JY, Yeon JH, Choi JW, Kwon SH, Kim BJ, Youn SW, Park KC, Huh CH. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol. 2014;53:1351–7.CrossRefGoogle Scholar
  9. 9.
    Gupta AK, Charrette A. Topical minoxidil: systematic review and meta-analysis of its efficacy in androgenetic alopecia. Skinmed. 2015;13:185–9.PubMedGoogle Scholar
  10. 10.
    Choi JW, Na SY, Park KC, Youn SW, Huh CH. Relation between treatment efficacy and cumulative dose of 3% topical minoxidil in male pattern baldness. J Am Acad Dermatol. 2012;66:e10–2.CrossRefGoogle Scholar
  11. 11.
    Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, Savin RC, Tharp MD. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50:541–53.CrossRefGoogle Scholar
  12. 12.
    Orfanos CE, Vogels L. Local therapy of androgenetic alopecia with 17 alpha-estradiol. A controlled, randomized double-blind study. Dermatologica. 1980;161:124–32.CrossRefGoogle Scholar
  13. 13.
    Kim JH, Lee SY, Lee HJ, Lee WS. The efficacy and safety of 17α-estradiol(Ell-Cranell alpha 0.025%) solution on female pattern hair loss: single center, open-label, non-comparative, phase IV study. Ann Dermatol. 2012;24:295–305.CrossRefGoogle Scholar
  14. 14.
    Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005;152:466–73.CrossRefGoogle Scholar
  15. 15.
    Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol. 1985;112:124–5.CrossRefGoogle Scholar
  16. 16.
    Peereboom-Wynia JD, van der Willigen AH, van Joost T, Stolz E. The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females. Acta Derm Venereol. 1989;69:395–8.PubMedGoogle Scholar
  17. 17.
    Budde J, Tronnier H, Rahlfs VW, Frei-Kleiner S. Systemic therapy of diffuse effluvium and hair structure damage. Hautarzt. 1993;44:380–4.PubMedGoogle Scholar
  18. 18.
    Park SY, Na SY, Kim JH, Cho S, Lee JH. Iron plays a certain role in patterned hair loss. J Korean Med Sci. 2013;28:934–8.CrossRefGoogle Scholar
  19. 19.
    Moftah N, Moftah N, Abd-Elaziz G, et al. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrastructural evaluation. J Eur Acad Dermatol Venereol. 2013;27:686–93.CrossRefGoogle Scholar
  20. 20.
    Kim H, Choi JW, Kim JY, Shin JW, Lee SJ, Huh CH. Low-level light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device-controlled multicenter trial. Dermatol Surg. 2013;39:1177–83.CrossRefGoogle Scholar
  21. 21.
    Lee SH, Zheng Z, Kang JS, Kim DY, Oh SH, Cho SB. Therapeutic efficacy of autologous platelet-rich plasma and polydeoxyribonucleotide on female pattern hair loss. Wound Repair Regen. 2015;23:30–6.CrossRefGoogle Scholar
  22. 22.
    Shin H, Ryu HH, Kwon O, Park BS, Jo SJ. Clinical use of conditioned media of adipose tissue-derived stem cells in female pattern hair loss: a retrospective case series study. Int J Dermatol. 2015;54:730–5.CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of DermatologySeoul National University and Seoul National University Bundang HospitalSeongnam-siRepublic of Korea

Personalised recommendations